{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:33:20Z","timestamp":1772166800350,"version":"3.50.1"},"reference-count":95,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012629","name":"Japan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012629","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cushing disease is a life-threatening disorder caused by autonomous secretion of ACTH from pituitary neuroendocrine tumors (PitNETs). Few drugs are indicated for inoperative Cushing disease, in particular that due to aggressive PitNETs. To explore agents that regulate ACTH-secreting PitNETs, we conducted high-throughput screening (HTS) using AtT-20, a murine pituitary tumor cell line characterized by ACTH secretion. For the HTS, we constructed a live cell\u2013based ACTH reporter assay for high-throughput evaluation of ACTH changes. This assay was based on HEK293T cells overexpressing components of the ACTH receptor and a fluorescent cAMP biosensor, with high-throughput acquisition of fluorescence images. We treated AtT-20 cells with compounds and assessed ACTH concentrations in the conditioned media using the reporter assay. Of 2480 screened bioactive compounds, over 50% inhibition of ACTH secreted from AtT-20 cells was seen with 84 compounds at 10 \u03bcM and 20 compounds at 1 \u03bcM. Among these hit compounds, we focused on thiostrepton (TS) and determined its antitumor effects in both in vitro and in vivo xenograft models of Cushing disease. Transcriptome and flow cytometry analyses revealed that TS administration induced AtT-20 cell cycle arrest at the G2\/M phase, which was mediated by FOXM1-independent mechanisms including downregulation of cyclins. Simultaneous TS administration with a cyclin-dependent kinase 4\/6 inhibitor that affected the cell cycle at the G0\/1 phase showed cooperative antitumor effects. Thus, TS is a promising therapeutic agent for Cushing disease. Our list of hit compounds and new mechanistic insights into TS effects serve as a valuable foundation for future research.<\/jats:p>","DOI":"10.1210\/endocr\/bqae089","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T02:18:57Z","timestamp":1721269137000},"source":"Crossref","is-referenced-by-count":2,"title":["High-throughput Screening for Cushing Disease: Therapeutic Potential of Thiostrepton via Cell Cycle Regulation"],"prefix":"10.1210","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1229-8962","authenticated-orcid":false,"given":"Takuro","family":"Hakata","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Sakyo-ku, Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-502X","authenticated-orcid":false,"given":"Ichiro","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Sakyo-ku, Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kosugi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Sakyo-ku, Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Sugawa","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Sakyo-ku, Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Sakyo-ku, Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Sakyo-ku, Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2197-2784","authenticated-orcid":false,"given":"Yohei","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Sakyo-ku, Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0254-6974","authenticated-orcid":false,"given":"Toshihito","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Sakyo-ku, Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-2370","authenticated-orcid":false,"given":"Daisuke","family":"Taura","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Sakyo-ku, Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-2593","authenticated-orcid":false,"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Medical Research Institute, Kitano Hospital, PIIF Tazuke-kofukai , Kita-ku, Osaka 530-8480 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"2024082704363013900_bqae089-B1","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","article-title":"Cushing's syndrome","volume":"402","author":"Gadelha","year":"2023","journal-title":"Lancet"},{"key":"2024082704363013900_bqae089-B2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1530\/EJE-19-0464","article-title":"High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry","volume":"181","author":"Valassi","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2024082704363013900_bqae089-B3","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing's syndrome: a cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2024082704363013900_bqae089-B4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024082704363013900_bqae089-B5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","article-title":"An individualized approach to the management of Cushing disease","volume":"19","author":"Fleseriu","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2024082704363013900_bqae089-B6","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","article-title":"Approach to the patient treated with steroidogenesis inhibitors","volume":"106","author":"Castinetti","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2024082704363013900_bqae089-B7","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11102-019-00984-6","article-title":"Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study","volume":"22","author":"Manetti","year":"2019","journal-title":"Pituitary"},{"key":"2024082704363013900_bqae089-B8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/cen.14081","article-title":"Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: a phase III extension study","volume":"91","author":"Fleseriu","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024082704363013900_bqae089-B9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"2024082704363013900_bqae089-B10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2024082704363013900_bqae089-B11","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40618-018-0936-7","article-title":"Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis","volume":"41","author":"Palui","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"2024082704363013900_bqae089-B12","doi-asserted-by":"crossref","first-page":"732240","DOI":"10.3389\/fendo.2021.732240","article-title":"Effectiveness of medical treatment of Cushing's disease: a systematic review and meta-analysis","volume":"12","author":"Sim\u00f5es Corr\u00eaa Galendi","year":"2021","journal-title":"Front Endocrinol"},{"key":"2024082704363013900_bqae089-B13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/EJE-16-0662","article-title":"Cabergoline for Cushing's disease: a large retrospective multicenter study","volume":"176","author":"Ferriere","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2024082704363013900_bqae089-B14","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2024082704363013900_bqae089-B15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2024082704363013900_bqae089-B16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng1501","article-title":"Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2","volume":"37","author":"Metherell","year":"2005","journal-title":"Nat Genet"},{"key":"2024082704363013900_bqae089-B17","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1038\/s41598-017-07820-6","article-title":"Red fluorescent protein-based cAMP indicator applicable to optogenetics and in vivo imaging","volume":"7","author":"Harada","year":"2017","journal-title":"Sci Rep"},{"key":"2024082704363013900_bqae089-B18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12020-017-1495-y","article-title":"Effects of growth hormone on thyroid function are mediated by type 2 iodothyronine deiodinase in humans","volume":"59","author":"Yamauchi","year":"2018","journal-title":"Endocrine"},{"key":"2024082704363013900_bqae089-B19","doi-asserted-by":"crossref","first-page":"bqac090","DOI":"10.1210\/endocr\/bqac090","article-title":"High-throughput screening in combination with a cohort study for iodothyronine deiodinases","volume":"163","author":"Yamauchi","year":"2022","journal-title":"Endocrinology"},{"key":"2024082704363013900_bqae089-B20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.4161\/cc.9.6.10955","article-title":"Thiazole antibiotics against breast cancer","volume":"9","author":"Halasi","year":"2010","journal-title":"Cell Cycle"},{"key":"2024082704363013900_bqae089-B21","unstructured":"Data from: \u00a0https:\/\/figshare.com\/articles\/figure\/Supplementary_materials_High-throughput_screening_for_Cushing_disease_therapeutic_potential_of_thiostrepton_via_cell_cycle_regulation_\/26157643"},{"key":"2024082704363013900_bqae089-B22","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1210\/clinem\/dgaa699","article-title":"Targeting corticotroph HDAC and PI3-kinase in cushing disease","volume":"106","author":"Zhang","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2024082704363013900_bqae089-B23","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cbin.10834","article-title":"Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells","volume":"41","author":"Wang","year":"2017","journal-title":"Cell Biol Int"},{"key":"2024082704363013900_bqae089-B24","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1210\/jc.2017-00464","article-title":"Histone deacetylase inhibitor SAHA is a promising treatment of cushing disease","volume":"102","author":"Lu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2024082704363013900_bqae089-B25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1507\/endocrj.EJ21-0778","article-title":"Effects of tubastatin A on adrenocorticotropic hormone synthesis and proliferation of AtT-20 corticotroph tumor cells","volume":"69","author":"Hagiwara","year":"2022","journal-title":"Endocr J"},{"key":"2024082704363013900_bqae089-B26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11102-014-0607-4","article-title":"Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells","volume":"18","author":"Sugiyama","year":"2015","journal-title":"Pituitary"},{"key":"2024082704363013900_bqae089-B27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm.3776","article-title":"A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease","volume":"21","author":"Riebold","year":"2015","journal-title":"Nat Med"},{"key":"2024082704363013900_bqae089-B28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000529710","article-title":"Silibinin, an HSP90 inhibitor, on human ACTH-secreting adenomas","volume":"113","author":"Pecori Giraldi","year":"2023","journal-title":"Neuroendocrinology"},{"key":"2024082704363013900_bqae089-B29","doi-asserted-by":"crossref","first-page":"111223","DOI":"10.1016\/j.celrep.2022.111223","article-title":"Pituitary adenomas evade apoptosis via noxa deregulation in Cushing's disease","volume":"40","author":"Asuzu","year":"2022","journal-title":"Cell Rep"},{"key":"2024082704363013900_bqae089-B30","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1158\/1535-7163.MCT-08-0188","article-title":"Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression","volume":"7","author":"Kwok","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2024082704363013900_bqae089-B31","doi-asserted-by":"crossref","first-page":"10387","DOI":"10.1007\/s11033-022-07751-0","article-title":"Effects of thiostrepton alone or in combination with selumetinib on triple-negative breast cancer metastasis","volume":"49","author":"Demirtas Korkmaz","year":"2022","journal-title":"Mol Biol Rep"},{"key":"2024082704363013900_bqae089-B32","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.18632\/oncotarget.2497","article-title":"Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells","volume":"5","author":"Zhang","year":"2014","journal-title":"Oncotarget"},{"key":"2024082704363013900_bqae089-B33","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1038\/s41388-019-0842-2","article-title":"Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton","volume":"38","author":"Hardy","year":"2019","journal-title":"Oncogene"},{"key":"2024082704363013900_bqae089-B34","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/neuonc\/noab155","article-title":"Newly established patient-derived organoid model of intracranial meningioma","volume":"23","author":"Yamazaki","year":"2021","journal-title":"Neuro Oncol"},{"key":"2024082704363013900_bqae089-B35","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.3390\/cancers14225594","article-title":"The expression of cell cycle-related genes in USP8-mutated corticotroph neuroendocrine pituitary tumors and their possible role in cell cycle-targeting treatment","volume":"14","author":"Mossakowska","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024082704363013900_bqae089-B36","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1073\/pnas.1018091108","article-title":"Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor","volume":"108","author":"Liu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024082704363013900_bqae089-B37","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1210\/jc.2015-1606","article-title":"Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for cushing disease","volume":"100","author":"Liu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2024082704363013900_bqae089-B38","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-08-4133","article-title":"HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas","volume":"69","author":"De Martino","year":"2009","journal-title":"Cancer Res"},{"key":"2024082704363013900_bqae089-B39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.2000.01088.x","article-title":"Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland","volume":"53","author":"Turner","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024082704363013900_bqae089-B40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4132\/jptm.2021.08.31","article-title":"Association of PTTG1 expression with invasiveness of non-functioning pituitary adenomas","volume":"56","author":"Kum","year":"2022","journal-title":"J Pathol Transl Med"},{"key":"2024082704363013900_bqae089-B41","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/clinem\/dgac588","article-title":"Treatment of cushing disease with pituitary-targeting seliciclib","volume":"108","author":"Liu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2024082704363013900_bqae089-B42","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"2024082704363013900_bqae089-B43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13046-018-0741-3","article-title":"The anti-tumor efficacy of CDK4\/6 inhibition is enhanced by the combination with PI3K\/AKT\/mTOR inhibitors through impairment of glucose metabolism in TNBC cells","volume":"37","author":"Cretella","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"2024082704363013900_bqae089-B44","doi-asserted-by":"crossref","first-page":"740002","DOI":"10.3389\/fonc.2021.740002","article-title":"Palbociclib induces senescence in melanoma and breast cancer cells and leads to additive growth arrest in combination with irradiation","volume":"11","author":"Jost","year":"2021","journal-title":"Front Oncol"},{"key":"2024082704363013900_bqae089-B45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41573-020-00117-w","article-title":"Image-based profiling for drug discovery: due for a machine-learning upgrade?","volume":"20","author":"Chandrasekaran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2024082704363013900_bqae089-B46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"2024082704363013900_bqae089-B47","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1210\/me.2004-0471","article-title":"Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas","volume":"19","author":"Fernando","year":"2005","journal-title":"Mol Endocrinol"},{"key":"2024082704363013900_bqae089-B48","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","article-title":"EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J Clin Invest"},{"key":"2024082704363013900_bqae089-B49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1507\/endocrj.EJ18-0491","article-title":"Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells","volume":"66","author":"Asari","year":"2019","journal-title":"Endocr J"},{"key":"2024082704363013900_bqae089-B50","first-page":"953","article-title":"Molecular mechanism of forkhead box M1 inhibition by thiostrepton in breast cancer cells","volume":"42","author":"Kongsema","year":"2019","journal-title":"Oncol Rep"},{"key":"2024082704363013900_bqae089-B51","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/eje.0.143r001","article-title":"Cyclin D and cyclin E expression in normal and adenomatous pituitary","volume":"143","author":"Jordan","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"2024082704363013900_bqae089-B52","first-page":"4651","article-title":"Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial-to-mesenchymal transition","volume":"18","author":"Li","year":"2019","journal-title":"Oncol Lett"},{"key":"2024082704363013900_bqae089-B53","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12920-022-01206-y","article-title":"The kinome, cyclins and cyclin-dependent kinases of pituitary adenomas, a look into the gene expression profile among tumors from different lineages","volume":"15","author":"Taniguchi-Ponciano","year":"2022","journal-title":"BMC Med Genomics"},{"key":"2024082704363013900_bqae089-B54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bbagrm.2014.11.008","article-title":"The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells","volume":"1849","author":"Hu","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"2024082704363013900_bqae089-B55","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.3892\/or.2014.3129","article-title":"Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer","volume":"31","author":"Kong","year":"2014","journal-title":"Oncol Rep"},{"key":"2024082704363013900_bqae089-B56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1479-5876-12-134","article-title":"Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer","volume":"12","author":"Wen","year":"2014","journal-title":"J Transl Med"},{"key":"2024082704363013900_bqae089-B57","doi-asserted-by":"crossref","first-page":"32298","DOI":"10.18632\/oncotarget.15764","article-title":"Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"2024082704363013900_bqae089-B58","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.acthis.2012.01.002","article-title":"FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer","volume":"114","author":"Chu","year":"2012","journal-title":"Acta Histochem"},{"key":"2024082704363013900_bqae089-B59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2407-8-42","article-title":"Tight correlation between expression of the forkhead transcription factor FOXM1 and HER2 in human breast cancer","volume":"8","author":"Bektas","year":"2008","journal-title":"BMC Cancer"},{"key":"2024082704363013900_bqae089-B60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1078-0432.CCR-12-1588","article-title":"The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis","volume":"19","author":"Li","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2024082704363013900_bqae089-B61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.7150\/jca.14461","article-title":"Prognostic significance of forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in angiosarcoma","volume":"7","author":"Ito","year":"2016","journal-title":"J Cancer"},{"key":"2024082704363013900_bqae089-B62","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrc3539","article-title":"Forkhead box proteins: tuning forks for transcriptional harmony","volume":"13","author":"Lam","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"2024082704363013900_bqae089-B63","doi-asserted-by":"crossref","first-page":"626836","DOI":"10.3389\/fonc.2020.626836","article-title":"FOXM1 and cancer: faulty cellular signaling derails homeostasis","volume":"10","author":"Kalathil","year":"2020","journal-title":"Front Oncol"},{"key":"2024082704363013900_bqae089-B64","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.3390\/cancers13123065","article-title":"FOXM1: a multifunctional oncoprotein and emerging therapeutic target in ovarian cancer","volume":"13","author":"Liu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024082704363013900_bqae089-B65","doi-asserted-by":"crossref","first-page":"9857","DOI":"10.2147\/CMAR.S270825","article-title":"Foxm1 is upregulated in osteosarcoma and inhibition of FoxM1 decreases osteosarcoma cell proliferation, migration, and invasion","volume":"12","author":"Zhu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"2024082704363013900_bqae089-B66","doi-asserted-by":"crossref","first-page":"10875","DOI":"10.1128\/MCB.25.24.10875-10894.2005","article-title":"Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (skp2-cks1) ubiquitin ligase","volume":"25","author":"Wang","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2024082704363013900_bqae089-B67","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ncb1217","article-title":"Foxm1 is required for execution of the mitotic programme and chromosome stability","volume":"7","author":"Laoukili","year":"2005","journal-title":"Nat Cell Biol"},{"key":"2024082704363013900_bqae089-B68","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1158\/0008-5472.CAN-04-4059","article-title":"Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe","volume":"65","author":"Wonsey","year":"2005","journal-title":"Cancer Res"},{"key":"2024082704363013900_bqae089-B69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2265.1994.tb02453.x","article-title":"Oncoprotein immunoreactivity in human pituitary tumours","volume":"40","author":"Raghavan","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024082704363013900_bqae089-B70","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jcp.49.10.795","article-title":"Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc","volume":"49","author":"Wang","year":"1996","journal-title":"J Clin Pathol"},{"key":"2024082704363013900_bqae089-B71","first-page":"253","article-title":"Post K. c-myc, c-fos, and c-myb gene expression in human pituitary adenomas","volume":"79","author":"Woloschak","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024082704363013900_bqae089-B72","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbagrm.2014.03.013","article-title":"Myc and cell cycle control","volume":"1849","author":"Bretones","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"2024082704363013900_bqae089-B73","doi-asserted-by":"crossref","first-page":"18693","DOI":"10.1038\/s41598-019-54917-1","article-title":"Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Sci Rep"},{"key":"2024082704363013900_bqae089-B74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12929-015-0163-x","article-title":"Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines","volume":"22","author":"Troadec","year":"2015","journal-title":"J Biomed Sci"},{"key":"2024082704363013900_bqae089-B75","doi-asserted-by":"crossref","first-page":"105170","DOI":"10.18632\/oncotarget.22005","article-title":"Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. But not for HPV pos. HNSCC cell lines","volume":"8","author":"Ziemann","year":"2017","journal-title":"Oncotarget"},{"key":"2024082704363013900_bqae089-B76","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11033-018-4222-8","article-title":"Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells","volume":"45","author":"Ozfiliz-Kilbas","year":"2018","journal-title":"Mol Biol Rep"},{"key":"2024082704363013900_bqae089-B77","doi-asserted-by":"crossref","first-page":"23505","DOI":"10.18632\/oncotarget.25239","article-title":"The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells","volume":"9","author":"Zocchi","year":"2018","journal-title":"Oncotarget"},{"key":"2024082704363013900_bqae089-B78","doi-asserted-by":"crossref","first-page":"e01675","DOI":"10.1016\/j.heliyon.2019.e01675","article-title":"Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model","volume":"5","author":"Saisomboon","year":"2019","journal-title":"Heliyon"},{"key":"2024082704363013900_bqae089-B79","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4062\/biomolther.2020.051","article-title":"Synergistic induction of apoptosis by the combination of an axl inhibitor and auranofin in human breast cancer cells","volume":"28","author":"Ryu","year":"2020","journal-title":"Biomol Ther (Seoul)"},{"key":"2024082704363013900_bqae089-B80","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.18632\/oncotarget.6516","article-title":"Auranofin-mediated inhibition of PI3K\/AKT\/mTOR axis and anticancer activity in non-small cell lung cancer cells","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"2024082704363013900_bqae089-B81","doi-asserted-by":"crossref","first-page":"e1191","DOI":"10.1038\/cddis.2014.132","article-title":"Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo","volume":"5","author":"Fan","year":"2014","journal-title":"Cell Death Dis"},{"key":"2024082704363013900_bqae089-B82","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.freeradbiomed.2006.12.021","article-title":"Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells","volume":"42","author":"Marzano","year":"2007","journal-title":"Free Radic Biol Med"},{"key":"2024082704363013900_bqae089-B83","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/acs.molpharmaceut.7b00764","article-title":"Drug repurposing approach identifies a synergistic drug combination of an antifungal agent and an experimental organometallic drug for melanoma treatment","volume":"15","author":"Riedel","year":"2018","journal-title":"Mol Pharm"},{"key":"2024082704363013900_bqae089-B84","doi-asserted-by":"crossref","first-page":"e0211268","DOI":"10.1371\/journal.pone.0211268","article-title":"Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis","volume":"14","author":"Varbanov","year":"2019","journal-title":"PLoS One"},{"key":"2024082704363013900_bqae089-B85","doi-asserted-by":"crossref","first-page":"e0171052","DOI":"10.1371\/journal.pone.0171052","article-title":"Repositioning approved drugs for the treatment of problematic cancers using a screening approach","volume":"12","author":"Varbanov","year":"2017","journal-title":"PLoS One"},{"key":"2024082704363013900_bqae089-B86","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/cr0300441","article-title":"Thiopeptide antibiotics","volume":"105","author":"Bagley","year":"2005","journal-title":"Chem Rev"},{"key":"2024082704363013900_bqae089-B87","doi-asserted-by":"crossref","first-page":"174661","DOI":"10.1016\/j.ejphar.2021.174661","article-title":"The bacterial thiopeptide thiostrepton. An update of its mode of action, pharmacological properties and applications","volume":"914","author":"Bailly","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"2024082704363013900_bqae089-B88","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1158\/1535-7163.MCT-11-0536","article-title":"Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts","volume":"10","author":"Wang","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2024082704363013900_bqae089-B89","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4161\/cbt.13.3.18875","article-title":"Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton","volume":"13","author":"Wang","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"2024082704363013900_bqae089-B90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijpharm.2018.12.001","article-title":"Development of co-solvent freeze-drying method for the encapsulation of water-insoluble thiostrepton in sterically stabilized micelles","volume":"556","author":"Esparza","year":"2019","journal-title":"Int J Pharm"},{"key":"2024082704363013900_bqae089-B91","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.xphs.2021.01.018","article-title":"Liposomal thiostrepton formulation and its effect on breast cancer growth inhibition","volume":"110","author":"Wongkhieo","year":"2021","journal-title":"J Pharm Sci"},{"key":"2024082704363013900_bqae089-B92","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.chembiol.2020.07.003","article-title":"Introduction to thiopeptides: biological activity, biosynthesis, and strategies for functional reprogramming","volume":"27","author":"Vinogradov","year":"2020","journal-title":"Cell Chem Biol"},{"key":"2024082704363013900_bqae089-B93","doi-asserted-by":"crossref","first-page":"15460","DOI":"10.1021\/jacs.7b08775","article-title":"Site- and stereoselective chemical editing of thiostrepton by rh-catalyzed conjugate arylation: new analogues and collateral enantioselective synthesis of amino acids","volume":"139","author":"Key","year":"2017","journal-title":"J Am Chem Soc"},{"key":"2024082704363013900_bqae089-B94","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/anie.201911886","article-title":"Cobalt(III)-catalyzed C\u2212H amidation of dehydroalanine for the site-selective structural diversification of thiostrepton","volume":"59","author":"Scamp","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"2024082704363013900_bqae089-B95","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1002\/anie.202011460","article-title":"Rapid and selective chemical editing of ribosomally synthesized and post-translationally modified peptides (RiPPs) via CuII-catalyzed \u03b2-borylation of dehydroamino acids","volume":"60","author":"de Vries","year":"2021","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqae089\/58662225\/bqae089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/9\/bqae089\/58875352\/bqae089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/9\/bqae089\/58875352\/bqae089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:37:16Z","timestamp":1724719036000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqae089\/7721529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":95,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,7,26]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqae089","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.22.581351","asserted-by":"object"}]},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,26]]},"article-number":"bqae089"}}